Anzeige
Mehr »
Samstag, 25.10.2025 - Börsentäglich über 12.000 News
Gold über 4.000 US-Dollar - Canary Gold startet Multi-Front-Exploration in Brasiliens neuem Gold-Hotspot
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9EK | ISIN: US36870W1009 | Ticker-Symbol: K5F
Stuttgart
24.10.25 | 21:54
5,400 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENENTA SCIENCE SPA ADR Chart 1 Jahr
5-Tage-Chart
GENENTA SCIENCE SPA ADR 5-Tage-Chart

Aktuelle News zur GENENTA SCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrGenenta Science Stock Jumps 85% On Strategic Collaboration With Anemocyte1
FrGenenta Science stock soars on strategic LVV Plasmid DNA collaboration3
FrGenenta and Anemocyte partner on lentiviral vector plasmid DNA tech13
FrGENENTA SCIENCE SPA: Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production1.200MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today...
► Artikel lesen
10.10.Genenta Science S.p.A. - 6-K, Report of foreign issuer1
03.10.Genenta Science S.p.A. - 6-K, Report of foreign issuer2
GENENTA SCIENCE Aktie jetzt für 0€ handeln
10.09.Genenta Science S.p.A. - 6-K, Report of foreign issuer1
01.08.Genenta Science S.p.A. - 6-K, Report of foreign issuer1
02.07.Genenta Science-Aktie behält Kaufempfehlung - Temferon vielversprechende Ergebnisse bei GBM zeigt1
02.07.Genenta Science stock maintains Buy rating as Temferon shows promise in GBM1
01.07.GENENTA SCIENCE SPA: Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals1
08.05.D.Boral Capital: Genenta Science Announces Participation in the D. Boral Capital Inaugural Global Conference202Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking...
► Artikel lesen
07.05.Genenta And Anemocyte Partner To Advance Immuno-Oncology Therapy Development1
19.03.GENENTA SCIENCE SPA: Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates203MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million)...
► Artikel lesen
09.01.GENENTA SCIENCE SPA: Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing491MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1